Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th – Conference Call to Follow

Rhea-AI Summary

Profound Medical (NASDAQ:PROF) will release its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026. Management will host a conference call at 4:30 p.m. ET the same day to review results and business developments. A live webcast and archived recording will be available in the company Investors section.

Key Figures

Earnings release date: March 5, 2026 Conference call time: 4:30 p.m. ET Results period: Full year 2025 +1 more

4 metrics

Earnings release date March 5, 2026 Q4 and full year 2025 results release after market close

Conference call time 4:30 p.m. ET Management call to discuss Q4 and full year 2025 results

Results period Full year 2025 Financial results coverage period

Quarter reported Fourth quarter 2025 Quarterly results to be discussed on call

Market Reality Check

Price: $6.23 Vol: Volume 110,845 is 0.53x t...

low vol

$6.23 Last Close

Volume Volume 110,845 is 0.53x the 20-day average of 210,222, indicating subdued trading ahead of the earnings date. low

Technical Shares at $6.23 are trading above the 200-day MA of $5.96, while still 30.39% below the 52-week high of $8.95.

Peers on Argus

PROF is up 1.26% while key device peers like OWLT (-4.36%), RCEL (-3.12%), LNSR ...

PROF is up 1.26% while key device peers like OWLT (-4.36%), RCEL (-3.12%), LNSR (-1.44%), and RPID (-7.87%) are down, with only SERA modestly higher at +1.56%, pointing to stock-specific positioning rather than a sector-wide move.

Common Catalyst Some peers, such as RCEL, also reported earnings-related news, but price moves are mixed rather than uniformly directionally aligned.

Historical Context

5 past events · Latest: Feb 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 05	Sonalleve usage milestone	Positive	-7.3%	PRO FAMILIA hospital reached 500th Sonalleve procedure and highlighted global usage.
Jan 27	Investor conferences	Neutral	-2.3%	Company outlined participation in two upcoming investor events in February 2026.
Jan 15	TULSA-PRO adoption	Positive	+9.4%	Mount Sinai performed its first TULSA-PRO procedure, expanding U.S. adoption.
Jan 12	Installed base update	Positive	+2.5%	Year-end TULSA-PRO installed base reached 78 systems, exceeding 2025 goal.
Jan 06	First commercial case	Positive	-0.5%	Johns Hopkins treated its first commercial TULSA-PRO prostate cancer patient.

Pattern Detected

Recent operational and commercial milestones often produced mixed reactions, with some positive updates sold off and others rewarded, suggesting inconsistent trading responses to good news.

Recent Company History

Over the past months, Profound reported several adoption and commercial milestones, including a 78-system TULSA-PRO installed base and major centers like Johns Hopkins and Mount Sinai initiating commercial or first procedures. Additional news highlighted a 500th Sonalleve procedure and upcoming investor events. Price reactions ranged from a +9.45% move on Mount Sinai’s TULSA update to a -7.33% decline on the Sonalleve milestone, indicating that positive operational news has not always translated into consistent share-price strength. Today’s scheduling of the Q4 and full-year 2025 release fits into this ongoing information flow.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2025-11-13

$150,000,000 registered capacity

An effective Form S-3 shelf filed on Nov 13, 2025 allows Profound to issue up to $150,000,000 in various securities, including common shares, warrants, debt, subscription receipts, and units, for working capital, capital expenditures, and general corporate purposes. No usage has been reported yet.

Market Pulse Summary

This announcement sets the timing for Profound’s Q4 and full year 2025 results on March 5, 2026 and ...

Analysis

This announcement sets the timing for Profound’s Q4 and full year 2025 results on March 5, 2026 and a management call at 4:30 p.m. ET. It follows recent updates on TULSA-PRO adoption and Sonalleve procedure milestones, which produced mixed share reactions. Investors may focus on how those operational gains translate into revenue, margins, and cash flow, against the backdrop of an unused $150,000,000 S-3 shelf that provides flexibility for future financing.

Key Terms

imri

1 terms

imri medical

"a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures"

iMRI (intraoperative magnetic resonance imaging) is the use of MRI scanners during a surgical procedure to provide real‑time images of a patient’s anatomy, helping surgeons see exactly where tissues, tumors, or instruments are while they operate. Investors care because iMRI can improve surgical accuracy, lower the need for follow‑up operations, and drive demand for specialized scanners, instruments and software—similar to giving surgeons a live GPS—which influences hospital purchasing, device sales and regulatory pathways.

AI-generated analysis. Not financial advice.

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures, will announce its fourth quarter and full year 2025 financial results after market close on Thursday, March 5, 2026.

Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the period.

Fourth Quarter and Full Year 2025 Results Conference Call Details:

Date: Thursday, March 5, 2026

Time: 4:30 p.m. ET

Live Call Registration: https://register-conf.media-server.com/register/BI9b6f3d29fd3749db83543442274147c2

The call will also be broadcast live and archived on the Company's website in the Investors section here.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets innovative interventional MRI (iMRI) procedures.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA Procedure™, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. The TULSA Procedure employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. The TULSA Procedure is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with the TULSA Procedure. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids, adenomyosis, pain palliation of bone metastases, desmoid tumors and osteoid osteoma. Sonalleve has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

For further information, please contact:

Stephen Kilmer
Investor Relations
skilmer@profoundmedical.com
T: 647.872.4849

FAQ

When will Profound Medical (PROF) announce Q4 and full year 2025 results?

Profound Medical will announce results after market close on Thursday, March 5, 2026. According to Profound, management will follow with a 4:30 p.m. ET conference call to discuss the financial results and recent business developments for the period.

What time is the Profound Medical (PROF) conference call on March 5, 2026?

The conference call is scheduled for 4:30 p.m. ET on March 5, 2026. According to Profound, the live call requires registration and the company will also broadcast and archive the presentation on its Investors website for later access.

How can investors join the Profound Medical (PROF) earnings call on March 5, 2026?

Investors can register for the live call via the provided registration link prior to the event. According to Profound, the call will also be broadcast live and an archived recording will be posted in the company Investors section for those unable to join live.

Will Profound Medical (PROF) provide a webcast or archive of the March 5, 2026 call?

Yes. Profound will broadcast the call live and archive the recording on its Investors website. According to Profound, the archived webcast will be available after the live event for investors and analysts to review the financial results and management commentary.

What will Profound Medical (PROF) discuss during the March 5, 2026 call?

Management will review fourth quarter and full year 2025 financial results and discuss business developments during the period. According to Profound, the call will cover the reported results and context around operations and strategic updates for investors.